PFS Benefit Shown With Maintenance Olaparib in BRCA1/2+ Advanced Ovarian Cancer
William H. Bradley, MD discusses the 5-year follow-up of the ongoing SOLO-1 trial, which is determining the efficacy of maintenance olaparib in patients with BRCA1/2-mutated advanced ovarian cancer.
William H. Bradley, MD, a gynecological oncologist at the Medical College of Wisconsin, discusses the 5-year follow-up of the ongoing SOLO-1 trial (NCT01844986), which is determining the efficacy of maintenance olaparib (Lynparza) in patients with BRCA1/2-mutated advanced ovarian cancer.
According to Bradley, there was significant benefit of maintenance olaparib compared to placebo in terms of progression free survival (PFS). Patients stopped receiving the study drug at 2 years, but the PFS benefit persisted at the 5-year follow-up. The survival benefit was durable.
The follow-up solidifies the use of maintenance therapy for patients with BRCA-mutated ovarian cancer, according to Bradley. Additionally, patients who received the maintenance therapy did not have significant persisting toxicities past the treatment period. Patients with blood malignancies such as acute myeloid leukemia did not get much worse over time.
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More
